Posted inClinical Updates news Public Health Specialties
The Dawn of the “No-Clinical-Trial” Era for Biosimilars: FDA’s Historic Ustekinumab Approval Shift
The US FDA's unprecedented exemption of clinical efficacy studies for a ustekinumab biosimilar marks a transformative regulatory milestone, reshaping biosimilar development, market dynamics, and patient access worldwide.
